Clinical trials: Atopic Asthma
Allergic Asthma
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
A single center pilot study to determine the protective effects of RhuMAB-E25 on airway physiology and biology in allergic asthmatics that undergo bronchoprovocation with methacholine.
- Trial name
- NCT00829179
- Testing
- RhuMab-E25
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Allergic Asthma
Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics
Asthma is a common respiratory disease of unknown etiology which currently affects approximately 7.5 % of the adult population ( ). Asthma is an inflammatory disorder of the airways.
- Trial name
- NCT00581048
- Testing
- Natural source d-α-tocopheryl acetate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Vanderbilt University
Asthma
Biomarkers of Irritant-Induced and Allergic Asthma
Asthma is a heterogeneous disease, and although much is understood about mechanisms of inflammation in allergic asthma, less is known about mechanisms of irritant-induced asthma (IA).
- Trial name
- NCT02740543
- Testing
- Fluticasone propionate HFA 220
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Asthma
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
The purpose of this trial is to compare the efficacy of 4 to 5 months of three treatments - omalizumab, corticosteroid therapy boost, and placebo - in reducing fall exacerbations in inner-city children and adolescents with…
- Trial name
- PROSE (NCT01430403)
- Testing
- Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS)
- Where
- 8 sites in United States
- Volunteers
- 478 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Effect of Anti-IgE in Non-Allergic Asthma
The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.
- Trial name
- NCT00162773
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Asthma
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
- Trial name
- SITAR (NCT01591044)
- Testing
- R940343 1mg, R940343 2mg
- Where
- 59 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Rigel Pharmaceuticals
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Asthma
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also.
- Trial name
- NCT01716754
- Testing
- QGE031, Omalizumab
- Where
- 150 sites in United States, Argentina and 22 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Asthma
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that…
- Trial name
- NCT00267202
- Testing
- Omalizumab, Immunotherapy
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis
Asthma, Allergic Rhinitis
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
- Conditions
- Asthma, Allergic Rhinitis, Atopic Dermatitis
- Trial name
- Xolair (NCT00367016)
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Wheezing, Asthma
Allergy Immunotherapy for the Reduction of Asthma
In this clinical study we aim to determine the effect of allergy immunotherapy in decreasing asthma and allergy related disease in children who had multiple episodes of wheezing and who are at high risk for developing persisting…
- Conditions
- Wheezing, Asthma, Allergy
- Trial name
- AIR (NCT01028560)
- Testing
- Allergen extracts (subcutaneous injections), Standard of care
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Albert Einstein College of Medicine
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Asthma
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when…
- Trial name
- NCT03052517
- Testing
- QAW039 150 mg, QAW039 450 mg
- Where
- 347 sites in United States, Argentina and 40 more
- Volunteers
- 2,538 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
The aim of this study is to evaluate the expression of IgE high affinity receptors (the part of the cell associated with allergic response) in patients suffering from uncontrolled severe asthma despite long term treatment with…
- Trial name
- NCT00454051
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Asthma
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair.
- Trial name
- XPORT (NCT01125748)
- Testing
- Omalizumab, Asthma therapies
- Where
- 100 sites in United States
- Volunteers
- 176 people
- Sponsor
- Genentech, Inc.
Asthma
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.
- Trial name
- NCT01836471
- Testing
- QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
- Where
- 76 sites in United States, Belgium and 8 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Severe IgE-mediated Asthma
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Assess efficacy and safety of omalizumab treatment during 12 months in order to reduce the use of inhaled corticosteroid (ICS) in pediatric and adult participants with severe Immunoglobulin E (IgE)-mediated asthma inadequately…
- Trial name
- MEXIC (NCT01912872)
- Testing
- Omalizumab, Budesonide, Formoterol
- Where
- 21 sites in Mexico
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Atopy
Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma is a disease of rapidly increasing incidence that already affects more than 17 million people in the United States alone.
- Trial name
- NCT01547286
- Testing
- Standardized Cat Allergen Extract and Standardized Dust Mite Allergen, Computed Tomography imaging, functional Positron Emission Tomography imaging, Nebulized methacholine inhalation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Allergy
Efficacy of SLITone in House Dust Mite Allergic Patients
This trial has been designed to evaluate the efficacy of specific immunotherapy with SLITone Dermatophagoides mix compared with placebo in subjects with house dust mite allergic asthma, based on asthma medication use during a…
- Trial name
- NCT00633919
- Testing
- SLITone(TM) Dermatophagoides mix, Salbutamol inhaler, Budesonide/formoterol inhaler
- Where
- Spain
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S